5:58 PM
 | 
Oct 24, 2008
 |  BC Extra  |  Clinical News

Omrix resumes Fibrin Pad trial

Omrix (NASDAQ:OMRI) gained $1.58 (12%) to $14.75 on Friday after it resumed a U.S. Phase II trial of Fibrin Pad...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >